← Back to All Filings

BeOne Medicines President & COO Sells $1.5M in ONC Stock

Low SignificanceNovember 19, 2025 at 5:02:21 PM EST

BeOne Medicines Ltd.

$ONC4CIK: 0001651308

Subscribe to track ONC

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

BeOne Medicines President & COO Sells $1.5M in ONC Stock

Company: BeOne Medicines Ltd. (ONC) Form: 4 | Filed: 2025-11-19 Significance: Low

Insider: Wu Xiaobin Title: President and COO | Relationship: Officer

Transaction: • Type: Sale • Shares: 3,991 American Depositary Shares • Price: ~$380.43 (weighted avg.) • Value: $1,518,303 • Owned After: 12,365 (Direct ADS)

Key Insight: The sale represents a negligible fraction (0.00375%) of the company's $40.48B market cap, indicating it is likely for personal financial management rather than a change in outlook.

Market Context: This is a routine insider sale, unlikely to have a material impact on the stock price given its small size relative to the company's valuation.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: BeOne Medicines Ltd. (ONC)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The President and COO, Wu Xiaobin, sold approximately $1.52 million worth of American Depositary Shares (ADS), a transaction of low significance given the company's large market capitalization.
  • Market Impact: The sale is too small to be considered material and is expected to have a neutral impact on the stock.

Company Information

FieldValue
CompanyBeOne Medicines Ltd.
Ticker SymbolONC
CIK0001651308
IndustryPharmaceutical Preparations

Insider Information

FieldValue
NameWu Xiaobin
CIK0001739452
Title/PositionPresident and COO
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-17
Transaction CodeS (Sale)
Security TypeAmerican Depositary Shares
Shares Involved3,991
Price Per Share$380.43 (Weighted Average)
Total Value$1,518,303.37
Shares Owned After12,365 (Directly owned ADS)
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$1,518,303.37
% of Market Cap0.00375%
Shares Transacted3,991
% of Shares OutstandingNot Available
Post-Transaction Ownership12,365 ADS (Direct) & 968,978 Ordinary Shares (Direct)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: With a market capitalization of $40.48 billion, this $1.52 million sale is negligible and represents only 0.00375% of the company's total value. Such transactions are common for executives at large-cap companies for liquidity or portfolio diversification.
  • Transaction Significance: The sale's value is far below the 0.1% of market cap threshold for moderate significance, classifying it as a routine, low-impact event.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction size is immaterial relative to the company's market capitalization and daily trading volume. It does not signal a change in the insider's conviction about the company's future prospects.

Volume & Sentiment

  • Expected Volume Impact: Minimal. The transaction is not large enough to cause a noticeable spike in trading volume.
  • Sentiment Indicator: Neutral. The market is unlikely to react to a sale of this size from a senior executive at a multi-billion dollar company.

Additional Context

Transaction Notes

  • The sale was executed in multiple transactions at weighted average prices, as detailed in the filing's footnotes. This is a standard practice for executing larger orders to minimize price impact.
  • Each American Depositary Share (ADS) represents 13 Ordinary Shares.
Topics:#SECFiling#InsiderTrading#ONC#BeOneMedicines#Form4#InsiderSell#StockMarket#Investing#Pharma

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.